The Latest Trading Price of Gujarat Terce Laboratories Ltd is ₹ 37.61 as of 30 Apr 15:30
. The P/E Ratio of Gujarat Terce Laboratories Ltd changed from 22.2 on March 2022 to 0 on March 2025 . This represents a CAGR of -100.00% over 4 yearsThe P/E Ratio of Venmax Drugs & Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Gujarat Terce Laboratories Ltd changed from ₹ 5.16 crore on March 2021 to ₹ 45.37 crore on March 2025 . This represents a CAGR of 54.46% over 5 yearsThe Market Cap of Venmax Drugs & Pharmaceuticals Ltd changed from ₹ 14.94 crore on March 2025 to ₹ 14.94 crore on March 2025 . This represents a CAGR of 0.00% over 1 years The revenue of Gujarat Terce Laboratories Ltd for the Dec '25 is ₹ 12.42 crore as compare to the Sep '25 revenue of ₹ 12.98 crore. This represent the decline of -4.31% The revenue of Venmax Drugs & Pharmaceuticals Ltd for the Dec '25 is ₹ 1.62 crore as compare to the Sep '25 revenue of ₹ 1.32 crore. This represent the growth of 22.73% The ebitda of Gujarat Terce Laboratories Ltd for the Dec '25 is ₹ 1.26 crore as compare to the Sep '25 ebitda of ₹ 1.94 crore. This represent the decline of -35.05% The ebitda of Venmax Drugs & Pharmaceuticals Ltd for the Dec '25 is ₹ 0.04 crore as compare to the Sep '25 ebitda of ₹ 0.05 crore. This represent the decline of -20% The net profit of Gujarat Terce Laboratories Ltd changed from ₹ -0.08 crore to ₹ 0.76 crore over 7 quarters. This represents a CAGR of NaN%
The net profit of Venmax Drugs & Pharmaceuticals Ltd changed from ₹ 0.01 crore to ₹ 0.03 crore over 7 quarters. This represents a CAGR of 87.34%
The Dividend Payout of Gujarat Terce Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Venmax Drugs & Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .
About Gujarat Terce Laboratories Ltd
Gujarat Terce Laboratories Limited, incorporated in 1985, produces branded generic formulations for the domestic market.
Over its more than three-decade business journey, the Company developed an extensive product basket comprising 50 brands covering multiple therapeutic areas which are marketed by its 180+ strong MR team across 13 Indian states.
Headquartered in Ahmedabad, the Company has its fully automated facility at Chhatral, in Gandhinagar, Gujarat
By 1986, Terce had established its presence in Gujarat and Rajasthan with a firm footing.
In 1992, the management raised public equity to give concrete shape and listed the Company on Bombay Stock Exchange.
In same year, Company established extensive manufacturing facility at Chhatral in Gandhinagar, Gujarat.
About Venmax Drugs & Pharmaceuticals Ltd
Venmax Drugs & Pharmaceuticals Limited, (VDPL) was initially incorporated as Private Company as 'Yenkay Medico Private Limited', on 28 September, 1998.
The Company thereafter changed its name to 'Yenkey Drugs & Pharmaceuticals Private Limited' on 18 January, 1995.
It became a Public Limited Company on February 3, 1995 as 'Yenkey Drugs & Pharmaceuticals Limited'.
Finally, the Company changed its name to 'Venmax Drugs & Pharmaceuticals Limited' on April 13, 2009.
For the past six months, Company focused on establishing chain of Medical Stores with a brand name as 'Ananya Pharma' under the Venmax Drugs & Pharma Limited, with the backing support of Formulations plant (Suzichem Labs).
At present, Company is engaged in the business of pharmaceutical products, drug intermediaries & API's etc.
The Company is developing the oncology products in R&D.
FAQs for the comparison of Gujarat Terce Laboratories Ltd and Venmax Drugs & Pharmaceuticals Ltd
Which company has a larger market capitalization, Gujarat Terce Laboratories Ltd or Venmax Drugs & Pharmaceuticals Ltd?
Market cap of Gujarat Terce Laboratories Ltd is 29 Cr while Market cap of Venmax Drugs & Pharmaceuticals Ltd is 28 Cr
What are the key factors driving the stock performance of Gujarat Terce Laboratories Ltd and Venmax Drugs & Pharmaceuticals Ltd?
The stock performance of Gujarat Terce Laboratories Ltd and Venmax Drugs & Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Gujarat Terce Laboratories Ltd and Venmax Drugs & Pharmaceuticals Ltd?
As of May 4, 2026, the Gujarat Terce Laboratories Ltd stock price is INR ₹37.61. On the other hand, Venmax Drugs & Pharmaceuticals Ltd stock price is INR ₹24.51.
How do dividend payouts of Gujarat Terce Laboratories Ltd and Venmax Drugs & Pharmaceuticals Ltd compare?
To compare the dividend payouts of Gujarat Terce Laboratories Ltd and Venmax Drugs & Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.